Navigation Links
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Date:8/28/2009

DEERFIELD, Ill. and OSAKA, Japan, Aug. 28 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

The alogliptin New Drug Application (NDA) was submitted in December 2007, and in the complete response for alogliptin dated June 26, 2009, the FDA requested an additional CV safety trial that satisfies the criteria outlined in the December 2008 "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes." The EXAMINE study is designed to comply with this Guidance.

"Takeda received FDA agreement to the design of the CV study and we are pleased to move forward with the study and collecting additional safety data so that the FDA can continue the review of the alogliptin NDA," said Nancy Joseph-Ridge, M.D., General Manager, Pharmaceutical Development Division. "We are committed to conducting this study to satisfy the CV safety requirements, leading to the enhancement of the product profile of alogliptin. While this trial is dependent on the occurrence of CV events, at this point we anticipate that we will be able to submit interim results to the FDA approximately two years after the study begins that will meet the FDA Guidance criteria for drug
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
11. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DALLAS , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Crystallography Scanner Industry, 2009-2019 is a professional and ... X-Ray Crystallography Scanner industry . The report firstly ... including its classification, application and manufacturing technology. The ... of X-Ray Crystallography Scanner listing their product specification, ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... landmark trial provide important insight for physicians in treating ... Corporation (NYSE: BSX ) today welcomed the ... this week,s issue of the New England Journal of ... Cardiovascular Research Foundation with research grant support from Boston ...
... over linezolid in resistance acquisition by Staph aureus ... meetingSAN DIEGO, Calif., May 6 Trius Therapeutics, ... the treatment of serious bacterial infections, announced today ... lead program, torezolid (TR-701), will be presented in ...
Cached Medicine Technology:Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 2Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 3Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 4Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 5Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases 2Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases 3
(Date:8/29/2014)... As reported by WKMS.com in the article ... Ohio municipal court drug has come up with a new ... serves as the presiding judge in a Southeastern Ohio municipal ... addicts a medicated treatment option that can literally prevent them ... as Vivitrol, which blocks receptors in the brain that would ...
(Date:8/29/2014)... August 29, 2014 As reported by CNN.com ... (8/15), the process of admitting that you need help ... The article acknowledges and highlights the fact that if you ... may be very overwhelmed by all of the information that ... impossible to sift through, it is still possible to get ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... According to new research presented in a Science ... to Prescription Drug Misuse Among Young Adults (8/16), peer ... olds when it comes to prescription drug abuse. Researchers from ... the real problem which influences misuse of prescription drugs is ... of them to have fun with other using friends. Evidently ...
(Date:8/29/2014)... 29, 2014 As reported by the Frederick News ... Court Grad (8/17), a graduate of the Frederick County Drug ... his own experience with the program. The graduate, Korey Shorb, put ... a 1 mile walk. He plans to donate the proceeds of ... to those who helped him. Shorb, who graduated in 2008, admitted ...
Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3
... , , , , ... and all MinuteClinic medical clinics throughout Arizona are now offering H1N1 ... MinuteClinic locations in Illinois in the Chicago area and in Nevada ... with no appointment necessary. Priority group restrictions have been lifted in ...
... ... tooth whitening procedures. , ... CA (PRWEB) Dec. 21, 2009 -- If you are thinking about giving the gift of ... have all the facts to become a smart shopper of this popular cosmetic process. , ...
... rats when resin was part of diet, study finds , ... in the Middle East -- known as myrrh -- may ... author explained that myrrh resin could be used in conjunction ... not clear yet how people might consume it, and more ...
... , CANTON, Mass., Dec. 21 Organogenesis, Inc. ... (PMA) with the U.S. Food and Drug Administration (FDA) for ... regeneration. If approved, CelTx will be the first, living ... market. , A pioneer in the field, Organogenesis ...
... , CHESTERFIELD, Mo., Dec. 21 ... scientific officer of Reliv International, Inc., was elected to the ... the nation,s leading trade association for the dietary supplement industry. ... control and manufacturing for Reliv, a direct selling company of ...
... , , SANTA CLARA, Calif., Dec. ... in enterprise mobility, today announced that it swept top honors ... MobileVillage® Mobile Star Awards(TM) program, as a result of industry ... and news services about mobile technology. , As in past ...
Cached Medicine News:Health News:CVS/pharmacy and MinuteClinic Now Providing H1N1 Vaccinations in Arizona 2Health News:CVS/pharmacy and MinuteClinic Now Providing H1N1 Vaccinations in Arizona 3Health News:Dreaming of a Whiter Christmas and New Year for Your Teeth? 2Health News:Organogenesis Files PMA for CelTx(TM) for Oral Soft Tissue Regeneration 2Health News:Organogenesis Files PMA for CelTx(TM) for Oral Soft Tissue Regeneration 3Health News:Reliv International's Carl W. Hastings Elected to Board of the Council for Responsible Nutrition 2Health News:Industry Names Agito Networks, Company CTO, FMC Customer to Top MobileVillage Honors for 2009 2Health News:Industry Names Agito Networks, Company CTO, FMC Customer to Top MobileVillage Honors for 2009 3Health News:Industry Names Agito Networks, Company CTO, FMC Customer to Top MobileVillage Honors for 2009 4
...
Enables Delicate Lifting Of The Flap Without Causing Trauma - Also available in Titanium...
Khosla Precision and Quality in Medical and Surgical Products....
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
Medicine Products: